Haematologica (Jan 2019)
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
- Rémy Gressin,
- Nicolas Daguindau,
- Adrian Tempescul,
- Anne Moreau,
- Sylvain Carras,
- Emmanuelle Tchernonog,
- Anna Schmitt,
- Roch Houot,
- Caroline Dartigeas,
- Jean Michel Pignon,
- Selim Corm,
- Anne Banos,
- Christiane Mounier,
- Jehan Dupuis,
- Margaret Macro,
- Joel Fleury,
- Fabrice Jardin,
- Clementine Sarkozy,
- Ghandi Damaj,
- Pierre Feugier,
- Luc Matthieu Fornecker,
- Cecile Chabrot,
- Veronique Dorvaux,
- Krimo Bouadallah,
- Sandy Amorin,
- Reda Garidi,
- Laurent Voillat,
- Bertrand Joly,
- Philippe Solal Celigny,
- Nadine Morineau,
- Marie Pierre Moles,
- Hacene Zerazhi,
- Jean Fontan,
- Yazid Arkam,
- Magda Alexis,
- Vincent Delwail,
- Jean Pierre Vilque,
- Loic Ysebaert,
- Steven Le Gouill,
- Mary B. Callanan,
- for the Lymphoma Study Association
Affiliations
- Rémy Gressin
- Onco-Hematology Department, Grenoble University Hospital;INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble-Alpes, Institute for Advanced Biosciences, Grenoble
- Nicolas Daguindau
- Hematology Department, Annecy Hospital
- Adrian Tempescul
- Hematology Department, Brest University Hospital
- Anne Moreau
- Pathology Department, Nantes University Hospital
- Sylvain Carras
- Onco-Hematology Department, Grenoble University Hospital
- Emmanuelle Tchernonog
- Hematology Department, Montpellier University Hospital
- Anna Schmitt
- Hematology Department, Cancer Institute Bergonie Bordeaux
- Roch Houot
- Hematology Department, Rennes University Hospital
- Caroline Dartigeas
- Hematology Department, Tours University Hospital
- Jean Michel Pignon
- Hematology Department, Dunkerque Hospital
- Selim Corm
- Hematology Department, Chambery Hospital
- Anne Banos
- Hematology Department, Bayonne Hospital
- Christiane Mounier
- Hematology Department, Loire Cancer Institute, Saint Etienne
- Jehan Dupuis
- Lymphoid Malignancies Unit, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil
- Margaret Macro
- IHBN - Hematology Department, Caen University Hospital
- Joel Fleury
- Hematology Department, Clermont-Ferrand Cancer Institute
- Fabrice Jardin
- Hematology Department, Rouen University Hospital
- Clementine Sarkozy
- Hematology Department, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud. INSERM 1052
- Ghandi Damaj
- Hematology Department, Amiens University Hospital
- Pierre Feugier
- Hematology Department, Nancy University Hospital
- Luc Matthieu Fornecker
- Hematology Department, University Hospital Strasbourg
- Cecile Chabrot
- Hematology Department, University Clermont-Ferrand Hospital
- Veronique Dorvaux
- Hematology Department, Metz University Hospital
- Krimo Bouadallah
- Hematology Department, Bordeaux University Hospital
- Sandy Amorin
- Hematology Department, University Hospital Paris Saint-Louis
- Reda Garidi
- Hematology Department, Saint Quentin Hospital
- Laurent Voillat
- Hematology Department, Chalon Hospital
- Bertrand Joly
- Hematology Department, Corbeil Hospital
- Philippe Solal Celigny
- Hematology Department, Victor Hugo Clinic, Le Mans
- Nadine Morineau
- Hematology Department, Catherine de Sienne Clinic, Nantes
- Marie Pierre Moles
- Hematology Department, Angers University Hospital
- Hacene Zerazhi
- Hematology Department, Avignon Hospital
- Jean Fontan
- Hematology Department, Besançon University Hospital
- Yazid Arkam
- Hematology Department, Mulhouse Hospital
- Magda Alexis
- Hematology Department, Orleans Hospital
- Vincent Delwail
- Onco-Hematology Department, University Hospital Poitiers and INSERM, CIC 1402, Poitiers University
- Jean Pierre Vilque
- Hematology Department, Baclesse Caen Cancer Center
- Loic Ysebaert
- Hematology Department, Toulouse University Hospital
- Steven Le Gouill
- Hematology Department, Nantes University Hospital
- Mary B. Callanan
- INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble-Alpes, Institute for Advanced Biosciences, Grenoble;Unit for Innovation in Genetics and Epigenetics in Oncology, Dijon University Hospital, France
- for the Lymphoma Study Association
- DOI
- https://doi.org/10.3324/haematol.2018.191429
- Journal volume & issue
-
Vol. 104,
no. 1
Abstract
We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrolled (median age, 73 years). Patients received a maximum of six cycles of treatment at 28-day intervals. The primary objective was to achieve an 18-month progression-free survival rate of 65% or higher. Secondary objectives were to evaluate toxicity and the prognostic impact of mantle cell lymphoma prognostic index, Ki67 expression, [18F]fluorodeoxyglucose-positron emission tomography and molecular minimal residual disease, in peripheral blood or bone marrow. With a median follow-up of 52 months, the 24-month progression-free survival rate was 70%, hence the primary objective was reached. After six cycles of treatment, 91% (54/59) of responding patients were analyzed for peripheral blood residual disease and 87% of these (47/54) were negative. Four-year overall survival rates of the patients who did not have or had detectable molecular residual disease in the blood at completion of treatment were 86.6% and 28.6%, respectively (P
